Research summary
Large outcome trials in heart failure form the bulk of this work. PARADIGM-HF randomized 8442 NYHA class II-IV HFrEF patients (EF ≤40%) to the angiotensin receptor-neprilysin inhibitor LCZ696 (sacubitril/valsartan) or enalapril, with the primary composite of cardiovascular death or HF hospitalization [1]. PARAGON-HF extended angiotensin-neprilysin inhibition to HFpEF, randomizing 4822 patients with EF ≥45%, elevated natriuretic peptides, and structural heart disease to sacubitril/valsartan or valsartan [8]. DAPA-HF assigned 4744 HFrEF patients to dapagliflozin or placebo regardless of diabetes status [2], and DELIVER assigned 6263 patients with EF >40% to dapagliflozin or placebo on top of usual therapy with a primary composite of worsening HF or cardiovascular death [6]. TOPCAT randomized 3445 HFpEF patients (EF ≥45%) to spironolactone or placebo with a primary composite of CV death, aborted cardiac arrest, or HF hospitalization over a mean 3.3-year follow-up [5]. MADIT-CRT enrolled 1820 patients with EF ≤30%, QRS ≥130 ms, and NYHA class I-II symptoms in a 3:2 randomization to CRT-D versus ICD alone, testing whether CRT prevents death or HF events in milder symptomatic disease [3]. VALIANT compared valsartan, captopril, and the combination in patients randomized 0.5-10 days after acute MI complicated by LV systolic dysfunction or heart failure, with mortality as the primary endpoint [7]. Outside heart failure, APOLLO randomized hereditary-transthyretin-amyloidosis-with-polyneuropathy patients 2:1 to the RNAi therapeutic patisiran (0.3 mg/kg every 3 weeks) or placebo, with the change from baseline in mNIS+7 at 18 months as the primary endpoint and Norfolk QOL-DN as a key secondary [4].
Recent publications
- Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of CardiologyDOI
- Guidelines for the Echocardiographic Assessment of the Right Heart in Adults: A Report from the American Society of EchocardiographyDOI
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart FailureDOI
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection FractionDOI
- Cardiac-Resynchronization Therapy for the Prevention of Heart-Failure EventsDOI
- Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin AmyloidosisDOI
- Spironolactone for Heart Failure with Preserved Ejection FractionDOI
- Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection FractionDOI
- Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or BothDOI
- Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection FractionDOI
The lab page does not clearly state student acceptance status. Email the professor directly to confirm.
How to apply
Email Scott D. Solomon 6-12 months before your application deadline. Read several recent papers and reference specific work in your message. Use our how to email a Japanese professor guide for the proven email structure.
For applications via MEXT scholarship: see our MEXT 2027 complete guide and university-specific University Recommendation track.
External profiles
- ORCID: https://orcid.org/0000-0003-3698-9597
- OpenAlex: openalex.org
Profile compiled from public sources (Researchmap, OpenAlex, Nagoya University faculty directory). Last refreshed 2026-05. Report incorrect information.